Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Pemetrexed.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Pemetrexed.
Anhydrous Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Pemetrexed.
Advertisement
Anthrax immune globulin, human
The risk or severity of adverse effects can be increased when Pemetrexed is combined with Anthrax immune globulin human.
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Pemetrexed.
BCG, Live, Connaught Strain
The risk or severity of adverse effects can be increased when Pemetrexed is combined with Bacillus calmette-guerin substrain connaught live antigen.
Advertisement
BCG, Live, Tice Strain
The risk or severity of adverse effects can be increased when Pemetrexed is combined with Bacillus calmette-guerin substrain tice live antigen.
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Pemetrexed.
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Pemetrexed.
Advertisement
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pemetrexed.
Clozapine
The risk or severity of adverse effects can be increased when Pemetrexed is combined with Clozapine.
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Pemetrexed.
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Pemetrexed.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Pemetrexed.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Pemetrexed.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Pemetrexed.
Digoxin
Digoxin may decrease the cardiotoxic activities of Pemetrexed.
Dipyrone
The risk or severity of myelosuppression can be increased when Metamizole is combined with Pemetrexed.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Pemetrexed.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Pemetrexed.
Fingolimod
Pemetrexed may increase the immunosuppressive activities of Fingolimod.
Hepatitis A Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Pemetrexed is combined with Hepatitis A Vaccine.
Hepatitis B Surface Antigen Vaccine
The risk or severity of adverse effects can be increased when Pemetrexed is combined with Hepatitis B Vaccine (Recombinant).
Leflunomide
The risk or severity of adverse effects can be increased when Pemetrexed is combined with Leflunomide.
Lipegfilgrastim
Pemetrexed may increase the myelosuppressive activities of Lipegfilgrastim.
Natalizumab
The risk or severity of adverse effects can be increased when Pemetrexed is combined with Natalizumab.
Ocrelizumab
Ocrelizumab may increase the immunosuppressive activities of Pemetrexed.
Ouabain
Ouabain may decrease the cardiotoxic activities of Pemetrexed.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Pemetrexed.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Pemetrexed.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pemetrexed.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Pemetrexed.
Rabies Immune Globulin, Human
The risk or severity of adverse effects can be increased when Pemetrexed is combined with Human rabies virus immune globulin.
Rabies Virus Vaccine Flury-Lep Strain
The risk or severity of adverse effects can be increased when Pemetrexed is combined with Rabies virus inactivated antigen, A.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Pemetrexed.
ROTAVIRUS VACCINE, LIVE
The risk or severity of adverse effects can be increased when Pemetrexed is combined with Rotavirus Vaccine.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The risk or severity of adverse effects can be increased when Pemetrexed is combined with Rubella virus vaccine.
Salmonella enterica subsp. enterica serovar typhi
The risk or severity of adverse effects can be increased when Pemetrexed is combined with Salmonella typhi ty21a live antigen.
sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pemetrexed.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Pemetrexed.
Tetanus Toxoid Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Pemetrexed is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
Tofacitinib
Pemetrexed may increase the immunosuppressive activities of Tofacitinib.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Pemetrexed.
Typhoid Vaccine Live Ty21a
The risk or severity of adverse effects can be increased when Pemetrexed is combined with Salmonella typhi ty21a live antigen.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The risk or severity of adverse effects can be increased when Pemetrexed is combined with Salmonella typhi ty2 vi polysaccharide antigen.
Varicella Virus Vaccine Live (Oka-Merck) strain
The risk or severity of adverse effects can be increased when Pemetrexed is combined with Varicella Zoster Vaccine (Live/Attenuated).
Yellow Fever Vaccine
The risk or severity of adverse effects can be increased when Pemetrexed is combined with Yellow Fever Vaccine.
Yellow-Fever Virus Vaccine, 17D-204 strain
The risk or severity of adverse effects can be increased when Pemetrexed is combined with Yellow Fever Vaccine.